Financial Performance Summary - In 2025, the company achieved total operating revenue of 230.72 million yuan, representing a growth of 666.65% compared to the previous year [1] - The net profit attributable to the parent company was a loss of 536.22 million yuan, which is a 32.74% reduction in losses year-on-year [1][2] - The net profit attributable to the parent company after deducting non-recurring gains and losses was a loss of 579.22 million yuan, with a 27.99% reduction in losses compared to the previous year [1] Asset and Equity Status - As of the end of the reporting period, the company's total assets amounted to 2.99 billion yuan, a decrease of 4.87% from the same period last year [2] - The equity attributable to the parent company was 1.58 billion yuan, down 25.49% year-on-year [2] Revenue and Profit Analysis - The significant increase in operating revenue is attributed to the expansion of the sales market for the company's first commercialized product, the Saliqi monoclonal antibody injection, which saw steady growth in sales [2] - The revenue from the licensing and commercialization agreement for the GR1803 injection also positively impacted the company's net profit during the reporting period [2] Drug Development Update - The company announced that its GR1802 injection for adult seasonal allergic rhinitis has passed the primary endpoint in Phase III clinical trials and the new drug application has been accepted by the National Medical Products Administration (NMPA) [4][5] - GR1802 is a fully human anti-IL-4Rα monoclonal antibody that specifically binds to the IL-4Rα on cell surfaces, inhibiting Th2-type inflammatory responses [6] Clinical Trials and Future Prospects - The GR1802 injection has multiple indications in clinical trials, including chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria, with various stages of clinical trials ongoing [6] - As of the announcement date, only two other drugs targeting the same receptor have been approved for marketing in China [7]

Core Viewpoint - The company Zhixiang Jintai-U (688443.SH) reported significant revenue growth for 2025, driven by the expansion of its first commercial product, but it still faces substantial net losses, indicating a distance from profitability [1][2]. Group 1: Financial Performance - In 2025, Zhixiang Jintai achieved total revenue of approximately 231 million yuan, representing a year-on-year increase of 666.65% compared to 2024 [1]. - The company reported a net loss attributable to shareholders of 536 million yuan, which is a reduction of 32.74% year-on-year [1]. - The net loss excluding non-recurring items was 579 million yuan, with a year-on-year decrease of 27.99% [1]. - As of the end of 2025, the total assets of the company were 2.993 billion yuan, a decrease of 4.87% from the previous year [1]. - The equity attributable to shareholders was 1.584 billion yuan, down 25.49% year-on-year [1]. Group 2: Product Development and Market Expansion - The revenue growth was primarily due to the market expansion of the first commercial product, the monoclonal antibody injection, Saliqi (金立希®), which saw steady sales growth [2]. - The company also benefited from significant licensing income related to the GR1803 injection, positively impacting net profit [2]. - Saliqi is the first fully human anti-IL-17A monoclonal antibody approved in China, with approvals for psoriasis and ankylosing spondylitis in August 2024 and January 2025, respectively [2]. - The company announced that the GR1802 injection for adult seasonal allergic rhinitis met its primary endpoint in Phase III clinical trials, and a new drug application has been submitted and accepted [2]. - Multiple indications for GR1802 are in clinical trials, including chronic sinusitis with nasal polyps and chronic spontaneous urticaria [2][3].

Core Viewpoint - The company, Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd., has achieved the primary endpoint in the Phase III clinical trial for its drug, Talizhi monoclonal antibody injection (GR1802), for the treatment of adult seasonal allergic rhinitis, and has submitted a new drug application to the National Medical Products Administration (NMPA) which has been accepted [1][2]. Group 1 - Talizhi monoclonal antibody injection (GR1802) is a fully human recombinant anti-IL-4Rα monoclonal antibody that specifically binds to human IL-4Rα on cell surfaces, blocking the binding of IL-4 and IL-13, thereby inhibiting the Th2 inflammatory response mediated by these cytokines [1]. - The drug has also received acceptance for a new drug application for the indication of moderate to severe atopic dermatitis in adults, which was submitted in September 2025 [1]. - Multiple other indications are in various stages of clinical trials, including chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria in Phase III, asthma in Phase II, and pediatric/adolescent atopic dermatitis in Phase Ib/IIa [1]. Group 2 - As of the announcement date, there are only two other drugs targeting the same mechanism that have been approved for marketing in China [2].

Core Viewpoint - Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. has submitted a new drug application for its Talizumab injection (GR1802) for the treatment of moderate to severe atopic dermatitis, which has achieved its primary endpoint in Phase III clinical trials [1][2]. Group 1: Drug Information - The drug Talizumab injection (GR1802) is a fully humanized monoclonal antibody targeting IL-4Rα, designed to inhibit Th2-type inflammatory responses by blocking the binding of IL-4 and IL-13 to IL-4Rα [2]. - Talizumab injection is currently undergoing clinical trials for multiple indications, including chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, and seasonal allergic rhinitis in adults and adolescents, all in Phase III trials, while asthma is in Phase II, and pediatric/adolescent atopic dermatitis is in Phase Ib/IIa [2]. Group 2: Regulatory Status - As of the announcement date, only two other drugs targeting the same pathway have been approved for marketing in China [3]. - The new drug application has been accepted by the National Medical Products Administration (NMPA) and is currently under review [1].

Core Viewpoint - Zhixiang Jintai (688443) announced that its drug Talichibai Injection (GR1802) has met the primary endpoint in a Phase III clinical trial for moderate to severe atopic dermatitis in adults, and the new drug application has been accepted by the National Medical Products Administration (NMPA) [1] Group 1 - The Phase III clinical trial for Talichibai Injection (GR1802) achieved its primary endpoint [1] - The company has submitted a new drug application for the indication to the NMPA, which has been accepted [1] - As of the announcement date, only two other drugs targeting the same indication have been approved for marketing in China [1]